Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection (GuideView)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04838626
Recruitment Status : Not yet recruiting
First Posted : April 9, 2021
Last Update Posted : April 9, 2021
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The purpose of this study is to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT). Tissue specimens from both the primary tumor and pelvic lymph nodes dissected during surgery from patients with newly-diagnosed high-risk prostate cancer (PCa) will be used for the histopathology assessments.

Approximately 195 participants will be enrolled to ensure that at least 156 participants complete the [18F]CTT1057 PET/CT scan procedure (i.e. investigational imaging agent administration and successful completion of the PET/CT scan), which will be required for the calculation of the co-primary endpoints.


Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Prostate Cancer Drug: [18F]CTT1057 Phase 2 Phase 3

Detailed Description:

This is a multi-center, single-arm, open-label prospective study to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors, using histopathology as SoT. Tissue specimens from both the primary tumor and pelvic lymph nodes dissected during surgery from patients with newly-diagnosed high-risk PCa will be used for the histopathology assessments.

All participants will receive [18F]CTT1057 for PET/CT scan imaging, and surgery (radical prostatectomy and extended pelvis lymph node dissection) will be performed up to 6 weeks after [18F]CTT1057 PET for pathology assessment of the tissue specimens.

The co-primary endpoints of patient-level sensitivity and region-level specificity will be assessed by comparing the central reading results of the [18F]CTT1057 PET scan to the histopathology results in the dissected tissue specimens, i.e. both the primary tumor and the dissected Pelvic Lymph Node (PLN)).

Pathology will be assessed by the local pathologists as per Standard of Care (SoC), who will be blinded to the PET data.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 195 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

All participants will receive [18F]CTT1057 for PET/CT scan imaging, and surgery will be performed up to 6 weeks after [18F]CTT1057 PET for pathology assessment of the tissue specimens.

Additional pharmacokinetics (PK) assessments will be performed on the date of imaging in a subset of approximately 10 patients at the same site.

Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Phase II/III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging for the Detection of PSMA Positive Tumors Using Histopathology as a Standard of Truth
Estimated Study Start Date : August 30, 2021
Estimated Primary Completion Date : December 26, 2022
Estimated Study Completion Date : December 26, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PET/CT imaging with [18F]CTT1057
All eligible participants will be enrolled to receive [18F]CTT1057 imaging agent on Day 1 and have PET/CT scan
Drug: [18F]CTT1057
PET/CT imaging with [18F]CTT1057
Other Name: Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan




Primary Outcome Measures :
  1. Patient-level sensitivity of [18F]CTT1057 [evaluated for all patients] [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Sensitivity of [18F]CTT1057 PET imaging, considering PSMA positive patients those who show at least one pathological [18F]CTT1057 uptake either in the primary tumor and/or metastatic pelvic lymph nodes (PLN) regions, with anatomically localized correspondence with the SoT.

  2. Region-level specificity of [18F]CTT1057 [evaluated for all regions] [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Specificity of [18F]CTT1057 PET imaging, defined as proportion of regions that test negative for lymph nodes on [18F]CTT1057 among those that are lymph node negative on the SoT


Secondary Outcome Measures :
  1. Patient-level specificity of [18F]CTT1057 [evaluated for all patients] [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Specificity of [18F]CTT1057 PET imaging, considering PSMA negative patients those who do not show any pathological [18F]CTT1057 uptake either in the primary tumor or metastatic lymph nodes and will be confirmed not having primary tumor or metastatic lymph nodes with the SoT

  2. Patient-level positive predictive value of [18F]CTT1057 [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Proportion of patients who are both [18F]CTT1057 and SoT positive (true positives (TP) among those who test positive on [18F]CTT1057 (TP+ false positives(FP))

  3. Patient-level negative predictive value of [18F]CTT1057 [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Proportion of patients who are both [18F]CTT1057 and SoT negative (true negatives (TN)) among those who test negative on [18F]CTT1057 (TN+false negatives (FN))

  4. Patient-level accuracy of [18F]CTT1057 [evaluated for all patients] [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Proportion of patients that are SoT and [18F]CTT1057 positive (TP) and negative (TN) among all patients enrolled (TP+TN+FP+FN)

  5. Region-level sensitivity of [18F]CTT1057 for patients excluding micro-metastasis [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Sensitivity of [18F]CTT1057 PET imaging in the PLN region, excluding from the analysis those lymph nodes showing metastasis <2mm (micro-metastasis)

  6. Region-level sensitivity of [18F]CTT1057 [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Proportion of PLN regions that test positive on both [18F]CTT1057 and SoT (TP) among those that are SoT positive (TP+FN)

  7. Region-level positive predictive value of [18F]CTT1057 [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Proportion of PLN regions that are SoT and [18F]CTT1057 positive (TP) among those regions that test positive on [18F]CTT1057 (TP+FP)

  8. Region-level negative predictive value of [18F]CTT1057 [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Proportion of PLN regions that are SoT and [18F]CTT1057 negative (TN) among those regions that test negative on [18F]CTT1057 (TN+FN)

  9. Region-level accuracy of [18F]CTT1057 [evaluated for all regions] [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Proportion of PLN regions that are SoT and [18F]CTT1057 positive (TP) and negative (TN) among all PLN regions assessed [18F]CTT1057 (TP+TN+FP+FN)

  10. Detection of distant metastasis in PS patients [evaluated for all regions] [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Number of distant metastasis identified at PET/CT scan in all patients, and percentage of patients with at least one lesion outside the prostate (primary tumor) identified by PET/CT scan

  11. Incidence of Treatment Emergent Adverse Events [ Time Frame: From first dosing (Day 1) up to 14 days post dosing ]
    The distribution of adverse events (AEs) within 14 days after each PET tracer administration will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.

  12. [18F]CTT1057 scan inter-reader variability [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Scan inter-reader variability is defined the agreement rate among reader determination of [18F]CTT1057 images.

  13. [18F]CTT1057 scan intra-reader variability [ Time Frame: [18F]CTT1057 PET imaging acquired at Day 1 assessed against histopathology as Standard of Truth (SoT) obtained during surgery within 6 weeks from [18F]CTT1057 scan ]
    Scan intra-reader variability is defined as the within-reader agreement rate of [18F]CTT1057 images.

  14. Observed maximum blood concentration (Cmax) of [18F]CTT1057 [ Time Frame: Day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post injection) ]
    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization in a subset of approximately 10 patients. Cmax will be listed and summarized using descriptive statistics.

  15. Time of maximum observed blood concentration occurrence (Tmax) of [18F]CTT1057 [ Time Frame: Day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post injection) ]
    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization in a subset of approximately 10 patients. Tmax will be listed and summarized using descriptive statistics.

  16. Area under the [18F]CTT1057 concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) [ Time Frame: Day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post injection) ]
    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization in a subset of approximately 10 patients. AUClast will be listed and summarized using descriptive statistics.

  17. Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of [18F]CTT1057 [ Time Frame: Day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post infusion) ]
    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization in a subset of approximately 10 patients. AUCinf will be listed and summarized using descriptive statistics.

  18. Terminal elimination half-life (T1/2) of [18F]CTT1057 [ Time Frame: Day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post injection) ]
    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization in a subset of approximately 10 patients. The half-life will be listed and summarized using descriptive statistics.

  19. Volume of distribution during the terminal phase following intravenous elimination (Vz) of [18F]CTT1057 [ Time Frame: Day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post injection) ]
    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization in a subset of approximately 10 patients. Vz will be listed and summarized using descriptive statistics.

  20. Total systemic clearance for intravenous administration (CL) of [18F]CTT1057 [ Time Frame: Day 1 (0, 0-5, 15, 30, 60, 120, 180-240, 300 minutes post injection) ]
    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization in a subset of approximately 10 patients. CL will be listed and summarized using descriptive statistics.

  21. Urinary excretion of radioactivity expressed as a percentage of injected activity (%IA) of [18F]CTT1057 [ Time Frame: Day 1 (pre-injection/0 hour, 0 hour (injection) - T (image acquisition starting time), T (image acquisition starting time) to 3 hours, 3 hours to 5 hours post imaging) ]
    Urine samples will be collected over specified time intervals and analyzed for radioactivity in a subset of approximately 10 patients. The radioactivity excreted in each interval as a percentage of injected activity (%IA) will be listed and summarized using descriptive statistics.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study
  • Untreated high risk biopsy-proven PCa patients according to D'Amico classification (Stage T2c or Prostate Specific Antigen (PSA) level >20ng/ml or Gleason score ≥8)
  • Scheduled or planned radical prostatectomy and extended pelvic lymph node resection up to 6 weeks after the investigational PET/CT scan followed by histopathology assessment
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Participants must be adults ≥ 18 years of age

Exclusion Criteria:

  • Inability to complete the needed investigational and standard-of-care imaging examinations due to any reasons (severe claustrophobia, inability to lie still for the entire imaging time, etc.)
  • Any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opinion of the Investigator, would indicate a significant risk to safety or impair study participation, including, but not limited to, current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, need of indwelling/condom catheters, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, and Coronavirus Disease 2019 (COVID-19)
  • Known allergy, hypersensitivity, or intolerance to [18F]CTT1057
  • Prior and current use of PSMA targeted therapies
  • Prior and current treatment with Luteinizing Hormone-Releasing Hormone (LHRH) analogues
  • Any prior Androgen Deprivation Therapy (ADT) (first or second generation) within 9 months before screening
  • Any 5-alpha reductase inhibitors within 30 days before screening
  • Patients with small cell or neuroendocrine PCa in more than 50% of biopsy tissue
  • Patients with incidental PCa after transurethral resection
  • Use of other investigational drugs within 30 days before screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04838626


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com

Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04838626    
Other Study ID Numbers: CAAA405A12302
2020-003958-67 ( EudraCT Number )
First Posted: April 9, 2021    Key Record Dates
Last Update Posted: April 9, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
[18F]CTT1057
Positron Emission Tomography/Computerized Tomography
PET/CT
Radioligand
Imaging
Primary Staging
PS
Standard of Truth
SoT
Prostate Cancer
PCa
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases